Tract Closure in PCNL

Recruiting N/A Interventional Study
Nephrolithiasis
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
92 (estimated)
Sponsor
Icahn School of Medicine at Mount Sinai · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a prospective, randomized controlled trial evaluating the effect of a hemostatic agent on tract-related bleeding during percutaneous nephrolithotomy (PCNL). Patients undergoing standardized PCNL will be randomized to receive either application of a hemostatic agent or no agent during tract closure, following uniform balloon occlusion, complete aspiration, and irrigation-free endoscopic ass…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria: * At least one stone ≥ 1.2cm * Scheduled to undergo planned PCNL * Age ≥ 18 years Exclusion criteria: * Unable to provide informed consent * Pre-existing nephrostomy tube * Multi access cases * Stone in calyceal diverticulum/hydrocalyx * Preoperatively planned overnight admiss…
Contacts

Mantu Gupta, MD

212-241-1272

mantu.gupta@mountsinai.org

CONTACT

Blair Gallante, MPH

212-241-1272

blair.gallante@mountsinai.org

CONTACT